Is Intellia Therapeutics, Inc. (NTLA) A Good Stock To Buy Now?
Is NTLA a good stock to buy? We came across a bullish thesis on Intellia Therapeutics, Inc. on Markman Capital Insight’s Substack.
Posts Tagged ‘NASDAQ:NTLA’
10 Stocks Stealing the Spotlight from Wall Street Giants
Wall Street’s three major indices all finished higher, with the Nasdaq leading gains by 3.07 percent, followed by the S&P 500 jumping 1.65 percent, and the Dow Jones, up 0.92...
Intellia (NTLA) Rockets 13% Ahead of Phase 3 Lonvo-Z Study Update
Intellia Therapeutics snapped a three-day losing streak on Thursday, soaring 13.29 percent to close at $14.75 apiece, as investors positioned portfolios ahead of the phase 3 results...
9 Stocks Crushing the Market With Surging Returns
Nine stocks posted strong gains on Thursday, bucking a mixed performance in the broader market, driven by positive company-specific developments that boosted buying appetite.
10 Most Shorted Mid-Cap and Small-Cap Stocks to Buy Now
Small cap and mid cap stocks have been on a roll in the first half of the year as investors rotate away from mega cap tech stocks.
10 Best Small-Cap Biotech Stocks to Buy According to Hedge Funds
On February 16, Franklin Equity said the biotechnology industry has entered 2026 on a firmer footing following an extended period of market uncertainty in the prior year, noting...
Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory
We came across a bullish thesis on Intellia Therapeutics, Inc. on Danny’s Substack by Danny Green.
Intellia Therapeutics (NTLA) Announces Fiscal Q4 and Full Year 2025 Financial Results
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the top gene therapy stocks to buy according to hedge funds. Intellia Therapeutics, Inc.
Top 10 Gene Therapy Stocks to Buy According to Hedge Funds
On February 23, Lauren Goodwin, New York Life Investments, appeared on CNBC’s ‘Closing Bell’ to talk about the state of equity markets and tariff uncertainties.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2025 Earnings Call Transcript
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2025 Earnings Call Transcript February 26, 2026Intellia Therapeutics, Inc. beats earnings expectations.
H.C. Wainwright Boosts Intellia (NTLA) Price Target After MAGNITUDE-2 Hold Lifted
Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the best innovative stocks to buy according to Wall Street analysts. H.C.
13 Best Innovative Stocks to Buy According to Wall Street Analysts
Innovation is entering a new phase of rapid acceleration, according to ARK Invest.
Baird Updates Intellia Therapeutics, Inc. (NTLA)’s Financial Model Following Nex-Z Clinical Hold Removal
TheFly reported on January 28 that Baird raised its price target on NTLA to $7 from $4 while maintaining a Neutral rating.
What Makes Intellia Therapeutics (NTLA) an Interesting Investment?
Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the “Contrarius Global Equity Fund”.
Intellia Therapeutics, Inc. (NTLA): A Bear Case Theory
We came across a bearish thesis on Intellia Therapeutics, Inc. on X.com by A_May_MD. In this article, we will summarize the bulls’ thesis on NTLA.
Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress
Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the most oversold biotech stocks to invest in. On November 11, Jones Trading dropped Intellia Therapeutics, Inc.
9 Oversold Biotech Stocks to Invest In
Biotech companies are making a solid comeback following an extended slump as investors shift their focus back to value and healthcare.
Evercore Downgrades Intellia (NTLA) Despite Strong ATTR Trial Data
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the best gene-editing stocks to buy according to hedge funds.
9 Best Gene-Editing Stocks to Buy According to Hedge Funds
Genetic manipulation – or gene editing – is a concept that describes altering the genetic material (DNA) of an organism.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q3 2025 Earnings Call Transcript
Operator: Hello, and welcome to Intellia Therapeutics Third Quarter 2025 Financial Results Conference Call. My name is Rocco, and I will be your conference operator today.
Intellia (NTLA) Soars 13% to Fresh High
Earlier this month, Intellia Therapeutics, Inc.
Intellia Therapeutics (NTLA) Soars to New High as Analysts Trigger ‘Buy’
During the session, Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2025 Earnings Call Transcript
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2025 Earnings Call Transcript August 7, 2025Intellia Therapeutics, Inc. beats earnings expectations.
Citizens JMP Maintains Neutral Stance on Intellia Despite Positive Lonvo-z Data
Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the best CRISPR stocks to buy. Citizens JMP reaffirmed its Market Perform rating on Intellia Therapeutics, Inc.
Top 10 CRISPR Stocks to Buy Now
Innovation is a hallmark of the biopharmaceutical sector, which is fueled by the demand for novel therapies to address unresolved medical needs.
Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds.
11 Best Genomics Stocks to Buy According to Hedge Funds
Genomics is the study of genes and how they operate.
Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is among the best NASDAQ stocks under $50 to buy. Analysts at H.C.
10 Best NASDAQ Stocks Under $50 to Buy
In this era where everyone is striving for the best, whether it be something in daily life or technology, the stock market is no exception.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2025 Earnings Call Transcript
Operator: Good morning, and welcome to Intellia' First Quarter 2025 Financial Results Conference Call. My name is Drew, and I will be your conference operator today.
10 Stocks Under $10 that Will Triple
As we delve into the discussion on stocks that will triple, we must shed light on the U.S.
8 Best Gene-Editing Stocks to Buy
Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to treat or prevent diseases.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2024 Earnings Call Transcript
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2024 Earnings Call Transcript February 27, 2025Intellia Therapeutics, Inc. beats earnings expectations.
Cathie Wood’s Stock Portfolio: 2025 Stock Picks
Cathie Wood is one of Wall Street's most contentious figures.
Top 11 CRISPR Stocks to Invest In
The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical challenges, and leveraging cutting-edge technologies like...
10 Best Gene Therapy Stocks to Buy Right Now
Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or prevent disease.
10 Worst ARK Stocks To Buy According to Short Sellers
Cathie Wood of ARK Investment is one of Wall Street's most well-known hedge fund bosses.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q3 2024 Earnings Call Transcript
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q3 2024 Earnings Call Transcript November 7, 2024Intellia Therapeutics, Inc. beats earnings expectations.
10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds
The pharmaceutical industry remains a hub of patent innovation, driven by evolving treatment paradigms, unmet medical needs, and the rising influence of technologies like pharmacogenomics...
10 Most Promising Biotech Stocks According to Hedge Funds
Biotechnology stocks are known for their high risk, making them some of the most volatile in the market.
10 Stocks That Will Change the World
If we were to try and summarize one of the biggest ways how to make money on the stock market, it'd include buying stocks of firms that have changed the world.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2024 Earnings Call Transcript
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2024 Earnings Call Transcript August 8, 2024Intellia Therapeutics, Inc. misses on earnings expectations.
Is Intellia Therapeutics, Inc. (NASDAQ:NTLA) the Most Promising Gene Therapy Stock to Buy Now?
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Intellia Therapeutics, Inc.
9 Best Gene Therapy Stocks to Buy Now
In this article, we will be discussing the best gene therapy stocks to buy now. Before we move on to our list, let's take a look at the market outlook for gene therapies and ...
15 Best ARK Stocks To Buy Now
Cathie Wood is one of the most polarizing, and prominent figures on Wall Street.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2024 Earnings Call Transcript
Operator: Good morning, and welcome to Intellia Therapeutics’ First Quarter 2024 Financial Results Conference Call.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2023 Earnings Call Transcript
Intellia Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.46, expectations were $-1.47. Intellia Therapeutics, Inc.
Top 11 CRISPR Stocks To Invest In
In this article, we discuss the top 11 CRISPR stocks to invest in.
13 Most Promising Future Stocks To Buy According To Hedge Funds
In this piece, we will take a look at the 13 most promising stocks to buy according to hedge funds.
Hedge Fund Resource Center
